This Acquirers Multiple Stock Appearing In Simons, Watsa, Pzena Portfolios

Johnny HopkinsStock ScreenerLeave a Comment

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

Pfizer Inc (PFE)

Pfizer is one of the world’s largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

A quick look at the price chart below shows us that the stock is down 9% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 7.80 which means that it remains undervalued.

PFE Chart

PFE data by YCharts

Superinvestors who currently hold positions in the company include:


Cliff Asness – 10,685,282

Ken Griffin – 4,050,961

Rich Pzena – 2,869,352

Bruce Kovner – 2,865,750

Ray Dalio – 2,838,472

Ken Fisher – 2,055,488

Jim Simons – 1,990,041

Israel Englander – 1,711,841

Cath Wood – 532,812

Prem Watsa – 460,900

For all the latest news and podcasts, join our free newsletter here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.